Insights into Urological Cancer

Manini, Claudia; López, José I.

doi:10.3390/cancers13020204

Cited by 4 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Urological cancer is a highly prevalent neoplastic disease with poor prognosis. Kidney cancer, bladder cancer and prostate cancer, which are the most common urological cancers, account for more than 33% of all male malignant tumors ( 1 , 2 ) Different urological cancers show different morphological or genetic characteristics, which pose difficulties to the diagnosis and treatment in clinical practice ( 3 , 4 ). Clinical symptoms of most urological cancers are non-specific, and a late diagnosis will increase the possibility of metastasis and adverse effects on the clinical outcome of patients ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

High Expression of SLC16A1 as a Biomarker to Predict Poor Prognosis of Urological Cancers

et al. 2021

View full text Add to dashboard Cite

ObjectiveTumor metabolism has always been the focus of cancer research. SLC16A1, as a key factor in catalysis of monocarboxylate transport across the plasma membrane, has been found to be associated with the occurrence and metastasis of a variety of cancers, but its prognostic significance and mechanism in different tumors are still unclear.MethodsBased on the gene expression matrix and clinical information of human cancer tissues acquired from TCGA and GTEX databases, the differential expression of SLC16A1 in different tumors and normal tissues was analyzed. To confirm the association between its expression, the mutation of MMRS gene, and the expression level of DNMTs. Univariate Cox regression was applied to analyze the association between SLC16A1 expression and patient prognosis. The effect of SLC16A1 expression on patient survival was examined by Kaplan Meier analysis. GSEA was used to identify related signaling pathways.ResultsThe expression of SLC16A1 was differentially expressed in most tumors, especially in the urinary tract where it is commonly highly expressed, and differential expression of SLC16A1 in different clinical stages. SLC16A1 expression was significantly positively correlated with MMRS gene mutation and DNMTS expression. Moreover, high SLC16A1 expression was associated with poorer overall survival (OS) and progression-free survival (PFS) in urological cancers. In particular, the results of the enrichment analysis showed that SLC16A1 was associated with processes such as cell adhesion and many signaling pathways affecting cell cycle were significantly enriched in the group with high-expressed SLC16A1.ConclusionSLC16A1 expression was upregulated in urological cancer. SLC16A1 may promote tumor development by regulating the epigenetic process of urological cancer and demonstrated a great potential as a prognostic biomarker of urological cancer patients.

show abstract

Section: Introductionmentioning

confidence: 99%

High Expression of SLC16A1 as a Biomarker to Predict Poor Prognosis of Urological Cancers

et al. 2021

View full text Add to dashboard Cite

show abstract

“… 14 - 17 This could be of particular importance given that malignancies, including urologic malignancies, progress at a widely variable and, in certain instances, unexpected rate and high patient accrual is mandated to achieve high evidence-based and accurate findings. 18 - 20 In addition, safety concerns are paramount, especially in malignancies, as patients tend to be immunocompromised and frail, making them prone to rapid deconditioning. Therefore, tailored protocols with rigorous safety measures must be implemented to ensure the safety of enrolled participants.…”

Section: Discussionmentioning

confidence: 99%

Understanding the Termination of Urologic Cancer Clinical Trials: Insights and Challenges

Alhajahjeh,

Hmeidan,

Elatrsh

et al. 2024

JCO Glob Oncol

View full text Add to dashboard Cite

PURPOSE Clinical trials are valuable evidence for managing urologic malignancies. Early termination of clinical trials is associated with a waste of resources and may substantially affect patient care. We sought to study the termination rate of urologic cancer clinical trials and identify factors associated with trial termination. METHODS A cross-sectional search of ClinicalTrials.gov identified completed and terminated kidney, prostate, and bladder cancer clinical trials started. Trials were assessed for reasons for termination. Multivariable analyses were conducted to determine the significant factors associated with the termination. RESULTS Between 2000 and 2020, 9,145 oncology clinical trials were conducted, of which 11.30% (n = 1,033) were urologic cancer clinical trials. Of the urologic cancer clinical trials, 25.38% (n = 265) were terminated, with low patient accrual being the most common reason for termination, 52.9% (n = 127). Multivariable analysis showed that only the university funding source odds ratio (OR) of 2.20 (95% CI, 1.45 to 3.32), single-center studies OR of 2.11 (95% CI, 1.59 to 2.81), and sample size of <50 were significant predictors of clinical trial termination OR of 5.26 (95% CI, 3.85 to 7.69); all P values are <.001. CONCLUSION The termination rate of urologic cancer clinical trials was 25%, with low accrual being the most frequently reported reason. Trials funded by a university, single-center trials, and small trials (sample size <50) were associated with early termination. A better understanding of these factors might help researchers, funding agencies, and other stakeholders prioritize resource allocations for multicenter trials that aim to recruit a sufficient number of patients.

show abstract

“…Notwithstanding their biological and clinical diversity, PCa, BlCa, and RCC constitute a significant clinical challenge [ 7 ], and owing to their clinically silent development at early stages, only the use of molecular biomarkers might enable early cancer detection, reducing mortality and increasing quality of life for these patients. At-risk populations, such as elderly people, smokers, workers exposed to occupational risk factors, and people with a family history of cancer or inherited conditions, would greatly benefit from effective screening tools [ 4 ].…”

Section: Discussionmentioning

confidence: 99%

“…Altogether, they are the second most incident and third deadliest group of neoplasms, worldwide [ 1 , 4 , 5 ]. Their rising incidence, as well as the economic burden associated with diagnosis, treatment, and follow-up procedures, constitute a major challenge and concern in healthcare [ 6 , 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

OncoUroMiR: Circulating miRNAs for Detection and Discrimination of the Main Urological Cancers Using a ddPCR-Based Approach

Sequeira,

Barros-Silva,

Ferreira-Torre

et al. 2023

IJMS

View full text Add to dashboard Cite

The three most common genitourinary malignancies (prostate/kidney/bladder cancers) constitute a substantial proportion of all cancer cases, mainly in the elderly population. Early detection is key to maximizing the patients’ survival, but the lack of highly accurate biomarkers that might be used through non-/minimally invasive methods has impaired progress in this domain. Herein, we sought to develop a minimally invasive test to detect and discriminate among those urological cancers based on miRNAs assessment through ddPCR. Plasma samples from 268 patients with renal cell (RCC; n = 119), bladder (BlCa; n = 73), and prostate (PCa; n = 76) carcinomas (UroCancer group), and 74 healthy donors were selected. Hsa-miR-126-3p, hsa-miR-141-3p, hsa-miR-153-5p, hsa-miR-155-5p, hsa-miR-182-5p, hsa-miR-205-5p, and hsa-miR-375-3p levels were assessed. UroCancer cases displayed significantly different circulating hsa-miR-182-5p/hsa-miR-375-3p levels compared to healthy donors. Importantly, the hsa-miR-155-5p/hsa-miR-375-3p panel detected RCC with a high specificity (80.54%) and accuracy (66.04%). Furthermore, the hsa-miR-126-3p/hsa-miR-375-3p panel identified BlCa with a 94.87% specificity and 76.45% NPV whereas higher hsa-miR-126-3p levels were found in PCa patients. We concluded that plasma-derived miRNAs can identify and discriminate among the main genitourinary cancers, with high analytical performance. Although validation in a larger cohort is mandatory, these findings demonstrate that circulating miRNA assessment by ddPCR might provide a new approach for early detection and risk stratification of the most common urological cancers.

show abstract

Insights into Urological Cancer

Cited by 4 publications

References 40 publications

High Expression of SLC16A1 as a Biomarker to Predict Poor Prognosis of Urological Cancers

High Expression of SLC16A1 as a Biomarker to Predict Poor Prognosis of Urological Cancers

Understanding the Termination of Urologic Cancer Clinical Trials: Insights and Challenges

OncoUroMiR: Circulating miRNAs for Detection and Discrimination of the Main Urological Cancers Using a ddPCR-Based Approach

Contact Info

Product

Resources

About